The other Achilles’ heel of BCR-ABL1

Inhibition of the BCR-ABL1 tyro-sine kinase with selective small molecule tyrosine kinase inhibitors such as imatinib, nilotinib or dasatinib has revolutionized the treatment of chronic myeloid leukemia (CML).[1][1],[2][2],[3][3] These drugs target the ATP-binding pocket of the ABL1 kinase domain